Table 3 Haematological and iron status measurements expressed as medians +/− SEM of Parkinson’s disease patients receiving 20 mg/kg/day (n = 6) or 30 (n = 5) mg/kg/day deferiprone or placebo (n = 8) for 6 months.
Months | Haemoglobin (109/L) | WBC (g/L) | Neutrophils (x109/L) | Platelets (x109/L) | Ferritin (ng/ml) | Serum Iron (nmol/L) | Transferrin Saturation (%) | |
|---|---|---|---|---|---|---|---|---|
Placebo | 0 | 141 ± 0.59 | 6.23 ± 0.41 | 3.95 ± 0.33 | 223 ± 18 | 100 ± 27 | 14 ± 1.2 | 25 ± 2.7 |
2 | 137 ± 0.61 | 5.58 ± 0.33 | 3.33 ± 0.20 | 222 ± 15 | 77 ± 19 | 16 ± 1.4 | 25 ± 2.6 | |
4 | 137 ± 0.63 | 5.98 ± 0.41 | 3.36 ± 0.31 | 219 ± 15 | 82 ± 21 | 15 ± 1.8 | 27 ± 4.1 | |
6 | 137 ± 0.55 | 5.78 ± 0.29 | 3.37 ± 0.13 | 220 ± 12 | 88 ± 21 | 17 ± 1.4 | 25 ± 2.9 | |
20 mg/kg/day Deferiprone | 0 | 136 ± 0.67 | 6.70 ± 0.81 | 4.08 ± 0.66 | 222 ± 20 | 189 ± 62 | 21 ± 2.1 | 32 ± 5.5 |
2 | 132 ± 0.81 | 6.78 ± 0.62 | 4.30 ± 0.59 | 237 ± 22 | 187 ± 62 | 22 ± 1.9 | 36 ± 5.4 | |
4 | 134 ± 0.63 | 6.93 ± 0.97 | 4.48 ± 0.78 | 215 ± 21 | 165 ± 59 | 18 ± 2.2 | 30 ± 2.4 | |
6 | 135 ± 0.63 | 6.61 ± 0.62 | 4.30 ± 0.56 | 224 ± 23 | 141 ± 47 | 18 ± 1.1 | 33 ± 6.6 | |
30 mg/kg/day Deferiprone | 0 | 141 ± 0.48 | 6.73 ± 0.66 | 4.38 ± 0.38 | 249 ± 17 | 132 ± 37 | 17 ± 1.9 | 24 ± 2.2 |
2 | 134 ± 0.41 | 6.38 ± 0.42 | 4.26 ± 0.20 | 229 ± 14 | 136 ± 50 | 21 ± 2.5 | 28 ± 1.9 | |
4 | 140 ± 0.27 | 5.63 ± 0.33 | 3.70 ± 0.23 | 217 ± 14 | 115 ± 41 | 20 ± 1.9 | 30 ± 1.7 | |
6 | 138 ± 0.32 | 6.05 ± 0.64 | 4.20 ± 0.53 | 223 ± 17 | 107 ± 38 | 19 ± 1.2 | 28 ± 2.9 |
